The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (The QoLiTax-Trial of the Arbeitsgemeinschaft Internistische Onkologie, AIO).

9621 Background: Docetaxel is a widely used cytotoxic agent. It causes a number of side effects, most frequently leukopenia and neutropenia, alopecia, nausea, diarrhea, and fatigue. This study evaluates the impact of docetaxel toxicities on patient’s health-related Quality of life (QoL). Methods: We conducted a multicenter, prospective, non-interventional trial, in which the QoL was assessed using the EORTC QLQ-C30 questionnaire at baseline and every 4 weeks up to 40 weeks in patients receiving a docetaxel-based chemotherapy for metastatic disease. The primary endpoint was the 4-months ≥5% deterioration rate of the global health status/QoL scale in patients with vs. those without grade 3/4 leukopenia or neutropenia. Secondary endpoints were the effect of other treatment-related adverse events on QoL. Uni- and multivariate analyses were applied. Results: From January 2008 to June 2011 a total of 2,659 patients were included. The majority of patients (48.1%) had prostate cancer, followed by breast (17.1%) a...